Biologics litigation raises remedy and external counsel concerns
With innovator-v-innovator cases growing, in-house counsel say they cannot always rely on trusted tactics for small molecule litigation, or even on some of their trusted law firm partners
The growing number of innovator-v-innovator cases in the biologics space is pushing in-house counsel to revisit litigation tactics and relationships with external counsel to try and adapt to different dynamics, according to sources at pharmaceutical manufacturers.
Counsel at five biologics...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.